Skip to main content

Table 3 Predictors of SF-36 component 12 weeks after DAA treatment

From: Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus

  Pain General health Energy/fatigue Health Change
Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate Bivariate Multivariate
RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p RR (95% CI) p
Male gender 1.05 (0.43–2.58) 1.000    3.14 (1.12–8.80) 0.005 6.21 (1.69–22.88) 0.006 1.79 (0.85–3.75) 0.111 2.78 (0.91–8.46) 0.072 2.07 (0.73–5.87) 0.196 0.37 (0.10–1.38) 0.140
Age ≤ 40 year 0.72 (0.42–1.26) 0.356    0.91 (0.67–1.25) 0.695    1.12 (0.79–1.60) 0.627    1.07 (0.66–1.73) 0.935   
University education 1.03 (0.59–1.77) 1,000    0.96 (0.71–1.29) 0.901    0.95 (0.70–1.30) 0.871    0.83 (0.53–1.29) 0.511   
Married versus not married 1.56 (0.63–3.88) 0.574    1.05 (0.49–2.27) 0.648    0.57 (0.26–1.25) 0.351    1.59 (0.71–3.57) 0.178 1.74 (0.75–4.01) 0.195
Married versus Widow/divorce 1.42 (0.47–4.26) 0.574    1.56 (0.61–4.00) 0.648    0.98 (0.38–2.50) 0.351    2.50 (0.84–7.40) 0.178 2.27 (0.75–6.90) 0.147
Regular worker versus non-regular 1.76 (0.78–3.96) 0.356    0.90 (0.44–1.85) 0.020 1.08 (0.50–2.35) 0.843 1.26 (0.62–2.56) 0.380    0.97 (0.47–2.02) 0.880   
Regular worker versus not working 1.42 (0.47–4.26) 0.356    3.69 (1.27–10.71) 0.020 2.52 (0.76–8.39) 0.132 2.00 (0.74–7.37) 0.380    1.26 (0.45–3.56) 0.880   
CD4 > 500 versus 350–500 1.06 (0.36–3.10) 0.957    0.60 (0.23–1.55) 0.676    0.84 (0.33–2.12) 0.914    0.62 (0.24–1.60) 0.206 0.55 (0.20–1.50) 0.244
CD4 > 500 versus < 350 0.86 (0.36–2.06) 0.957    0.84 (0.39–1.83) 0.676    0.84 (0.39–1.83) 0.914    0.62 (0.28–1.37) 0.206 0.55 (0.23–1.29) 0.169
HCV-RNA > 800,000 IU/mL 0.99 (0.52–1.88) 1,000    0.97 (0.69–1.37) 1,000    0.94 (0.66–1.32) 0.861    0.78 (0.49–1.23) 0.399   
Interferon failure 0.56 (0.15–2.08) 0.515    0.99 (0.58–1.67) 1,000    1.02 (0.60–1.72) 1,000    1.81 (1.11–2.95) 0.069 3.09 (0.96–10.01) 0.059
Achieving SVR12 0.91 (0.27–3.05) 1,000    0.75 (0.46–1.23) 0.455    1.90 (0.58–6.20) 0.253    0.85 (0.35–2.05) 0.706   
Non-smoker 1.01 (0.59–1.75) 1,000    0.89 (0.66–1.20) 0.564    0.89 (0.66–1.21) 0.564    1.05 (0.69–1.62) 0.950   
BMI normal versus underweight 1.20 (0.40–3.64) 0.659    0.66 (0.24–1.80) 0.437    0.60 (0.22–1.65) 0.440    0.40 (0.15–1.08) 0.177 0.45 (0.16–1.28) 0.135
BMI normal versus overweight/obese 1.54 (0.60–3.98) 0.659    1.37 (0.62–3.02) 0.437    1.26 (0.57–2.77) 0.440    0.90 (0.39–2.06) 0.177 0.68 (0.27–1.69) 0.403
Non-IVDU 1.22 (0.56–2.68) 0.763    0.32 (0.11–0.89) 0.005 0.27 (0.07–1.13) 0.072 0.94 (0.56–1.57) 1,000    1.23 (0.67–2.24) 0.720   
Fibrosis stage F0–F1 versus F2–F3 1.00 (0.37–2.66) 0.276    1.28 (0.55–2.94) 0.243 1.69 (0.70–4.08) 0.240 1,20 (0.52–2.75) 0.298    0.76 (0.32–1.80) 0.690   
Fibrosis stage F0–F1 versus F4 0.50 (0.20–1.22) 0.276    2.06 (0.88–4.85) 0.243 2.85 (1.16–7.00) 0.023 0.55 (0.23–1.32) 0.298    0.72 (0.30–1.71) 0.690   
Non-anemia 0.58 (0.33–1.04) 0.141 0.46 (0.19–1.13) 0.090 1.16 (0.75–1.80) 0.621    1,40 (0.84–2,32) 0.221 1.68 (0.68–4.12) 0.261 1.63 (0.79–3.39) 0.228 1.52 (0.52–4.56) 0.453
NNRTI-based versus PI-based ART 1.76 (0.60–5.16) 0.402    1.17 (0.71–1.93) 0.674    1.14 (0.69–1.88) 0.771    1.85 (0.75–4.53) 0.212 2.47 (0.76–8.00) 0.132
  1. HCV-RNA: hepatitis C virus ribonucleic acid; SVR12: sustained virological response at 12 weeks post treatment; BMI: body mass index; IVDU: intravenous drug user; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; ART: antiretroviral therapy